NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic solutions developer, announced today that its strategic partner, Clinilabs, will utilize QTinno®, NewCardio's automated cardiac safety solution, to conduct a Phase I trial of an investigational new drug under development for a central nervous system (CNS) indication. The assessment of cardiac safety will be one important aspect of the trial.
Clinilabs, located in New York City, is a full-service contract research organization that provides early-phase and specialty clinical drug development services to industry. Clinilabs has integrated QTinno into its current core lab offerings as part of its strategic initiative to deliver a full portfolio of cardiac safety and cardiac core laboratory services to industry. Providing fully automated ECG analysis as an integrated service offering, empowered by QTinno, enables Clinilabs to provide the complete range of ECG processing services now requested by pharma companies interested in assessing the cardiac safety of drugs in development.
"We are a trusted CRO with expertise in early phase development, which hinges on the assessment of drug safety and tolerability. The integration of QTinno into our ECG core laboratory enhances our ability to assess cardiac safety by using the industry's leading automated ECG solution," commented Dr. Gary Zammit, President and CEO of Clinilabs. "We are a one-stop-shop. Our 50-bed Phase I unit uses Holter telemetry to generate ECGs that are read in our own ECG core laboratory. Our clients are served by one vendor, one project manager, and one seamless system for completing cardiac safety studies. The integration of QTinno into our ECG core laboratory truly differentiates us from other providers in that it allows us to analyze ECGs using the most advanced technology in the industry today."
Vincent Renz, NewCardio President and Chief Executive Officer, commented, "NewCardio is excited to support Clinilabs in the integration of QTinno in order to enhance their expertise in assessing drug safety in early phase development. Securing opportunities, such as this study, is proof that our partnership with Clinilabs is delivering value to both organizations and leading the way for best practices in cardiac safety. We look forward to continuing to work together as the industry continues in its adoption of QTinno's superior technology which offers more accurate and precise cardiac safety data in a more timely and cost effective manner."
NewCardio's innovative 3D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead ECG. NewCardio's lead product is QTinno, a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety markers for the pharmaceutical industry and drug regulators. The Company believes that QTinno, a software-based, analytical technology is the industry's leading solution for the delivering accurate and precise analysis of ECGs in a fully automated process to determine cardiac toxicity during drug development, with the added benefit of significant time and cost efficiencies.
Increased emotional sensitivity linked to previous COVID-19 infection, new research suggests